Lampalizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lampalizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetCFD
Clinical data
Routes of
administration
Intravitreal
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC2068H3214N546O676S13
Molar mass46.96 kg/mol g·mol−1

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.[1][2]

One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.[4]

These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.[5]

References[edit]

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
  3. ^ "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration". www.roche.com. Retrieved 2017-09-14.
  4. ^ "Statement on Chroma Study". www.roche.com. Retrieved 2017-11-10.
  5. ^ Dolgin, E (9 November 2017). "Age-related macular degeneration foils drugmakers". Nature Biotechnology. 35 (11): 1000–1001. doi:10.1038/nbt1117-1000. PMID 29121027.